WO2009118750A1 - Hydrolyse stéreosélective pour la résolution de mélanges racémiques à base de (±) -cis-s-acétoxy-1- (4-méthoxyphényl) -4- (2-furyl) -2-azétidinone, de (±) -cis-s-acétoxy-1- (4-méthoxyphenyl) -4- (2-thiényl) -2-azétidinone, ou de (±)-cis-3-acétoxy-4-(1,1-diméthyléthyl)-2-azétidinone - Google Patents

Hydrolyse stéreosélective pour la résolution de mélanges racémiques à base de (±) -cis-s-acétoxy-1- (4-méthoxyphényl) -4- (2-furyl) -2-azétidinone, de (±) -cis-s-acétoxy-1- (4-méthoxyphenyl) -4- (2-thiényl) -2-azétidinone, ou de (±)-cis-3-acétoxy-4-(1,1-diméthyléthyl)-2-azétidinone Download PDF

Info

Publication number
WO2009118750A1
WO2009118750A1 PCT/IN2008/000722 IN2008000722W WO2009118750A1 WO 2009118750 A1 WO2009118750 A1 WO 2009118750A1 IN 2008000722 W IN2008000722 W IN 2008000722W WO 2009118750 A1 WO2009118750 A1 WO 2009118750A1
Authority
WO
WIPO (PCT)
Prior art keywords
azetidinone
acetoxy
methoxyphenyl
formula
furanyl
Prior art date
Application number
PCT/IN2008/000722
Other languages
English (en)
Inventor
Naveen Anand
Surrinder Koul
Subhash Chandra Taneja
Rajinder Parshad
Kuldip Singh Manhas
Rattan Lal Sharma
Ghulam Nabi Qazi
Original Assignee
Council Of Scientific & Industrial Research
University Of Jammu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Of Scientific & Industrial Research, University Of Jammu filed Critical Council Of Scientific & Industrial Research
Publication of WO2009118750A1 publication Critical patent/WO2009118750A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings

Definitions

  • the present invention relates to a stereoselective enzymatic process for the resolution of a mixture of ( ⁇ )-cis-3-acetoxy-1-(4-methoxyphenyl)-4-(2-furanyl)-2- azetidinone, ( ⁇ )-cis-3-acetoxy-1-(4-methoxyphenyl)-4-(2-thiophenyl)-2-azetidinone and ( ⁇ )-cis-3-acetoxy-4-(1 ,1-dimethylethyl)-2-azetidinone into their optically pure forms.
  • the present invention relates to a process for the resolution of a mixture of ( ⁇ )-cis-3-acetoxy-1-(4-methoxyphenyl)-4-(2-furanyl)-2- azetidinone, ( ⁇ )-cis-3-acetoxy-1-(4-methoxyphenyl)-4-(2-thiophenyl)-2-azetidinone and ( ⁇ )-cis-3-acetoxy-4-(1 ,1-dimethylethyl)-2-azetidinone into their optically pure forms by using a lipase enzyme.
  • the invention discloses the use of a native lipase enzyme preparation Arthrobacter simplex (MTCC 5125) in a highly efficient resolution process for the separation of two enantiomers of ( ⁇ )-c/s-3-acetoxy-1-(4- methoxyphenyl)-4-(2-furanyl)-2-azetidinone, ( ⁇ )-c/s-3-acetoxy-1-(4-methoxyphenyl)- 4-(2-thiophenyl)-2-azetidinone and ( ⁇ )-c/s-3-acetoxy-4-(1 ,1-dimethylethyl)-2- azetidinone through stereoselective hydrolysis of their acetyl esters in presence of an organic co-solvent.
  • MTCC 5125 native lipase enzyme preparation Arthrobacter simplex
  • paclitaxel [Taxol®], a complex polycyclic diterpene, exhibits a unique mode of action on microtubule proteins responsible for the formation of the spindle during cell division. Paclitaxel inhibits the depolymerization process of microtubulin.
  • Various types of cancers have been treated with paclitaxel and results in the treatment of ovarian cancer and metastatic breast cancer are very promising.
  • Paclitaxel was originally isolated from the bark of the yew Taxus brevifolia and has also been found in other Taxus sp. in relatively low yield.
  • Paclitaxel is 1000 times more potent compared to 10- deacetyl baccatin-lll and its higher activity is due to C-13 side chain comprising N-benzoyl-(2f?,3S)-3-phenylisoserine moiety (Wani et al JAm Chem Soc. 93, 2325- 7 1971).
  • paclitaxel Due to the poor solubility of paclitaxel, various groups are involved in the development of more water soluble taxane analogs and other molecules having more efficacy than parent molecule. Higher water soluble taxol derivative have also been developed, which when given orally was as effective as i.v dose. Paclitaxel and was also found active in a human, hormone-dependent, prostate tumor model CWR-22 and just as effective in anti-androgen chemotherapy (Patel et al, Tetrahedron: Asymmetry, 2003, 14, 3673-3677).
  • Optically enriched (+)-c/s-(3R,4f?)-3-acetoxy-1 -(4-methoxyphenyl)-4-(2- furanyl)-2-azetidinone of formula 1a, (+)-c/s-(3R,4R)-3-acetoxy-1-(4- methoxyphenyl)-4-(2-thiophenyl)-2-azetidinone of formula 2a and (+)-c/s-(3R,4S)-3- acetoxy-4-(1 ,1-dimethylethyl)-2-azetidinone of formula 3a are the key side chain intermediates used in the synthesis of modified side-chain of new generation analogues of anticancer drug Paclitaxel.
  • Amano PS- 30 Pseudomonas cepacia
  • Amano GC-20 Geotrichum candidum
  • Amano APF Aspergillus niger Amano AK (Pseudomonas sp.)
  • Amano Lipase P-30 Pseudomonas sp.
  • Amano P Pseudomonas fluorescens
  • Amano AY-30 Candida cylindracea
  • Amano N Rhizopus niveus
  • Amano R Piericillium sp.
  • Amano FAP Rhizopus oryzae
  • Amano AP-12 Aspergillus nige ⁇ , Amano MAP (Mucor meihei), Amano GC-4 (Geotrichum candidum), Sigma L-0382 and L-3126 (porcine pancrease), Lipase OF (Sepracor), Esterase 30,000 (Gist-Brocard
  • Holtan et al. (US Patent No. 6548293) patented a process comprising selective hydrolyses of the ester of one of the enantiomers of ⁇ -lactam by combining the mixture with homogenized avian or mammalian liver.
  • MTCC 5125 for the kinetic resolution of ( ⁇ )- c/s-3-acetoxy-1 -(4-methoxyphenyl)-4-(2-furanyl)-2-azetidinone, ( ⁇ )-c/s-3-acetoxy-1 - (4-methoxyphenyl)-4-(2-thiophenyl)-2-azetidinone, ( ⁇ )-c/s-3-acetoxy-4-(1 , 1 - dimethylethyl)-2-azetidinone of the formulae 1-3 is novel and has not been reported in the literature or known in the art of synthesis of precursors of taxol side chain.
  • the present invention thus discloses in detail the application of Arthrobacter simplex (RRL-1) lipase for the kinetic resolution of racemic ( ⁇ )-c/s-3-acetoxy-1-(4- methoxyphenyl)-4-(2-furanyl)-2-azetidinone, ( ⁇ )-c/s-3-acetoxy-1-(4-methoxyphenyl)- 4-(2-thiophenyl)-2-azetidinone, ( ⁇ )-c/s-3-acetoxy-4-(1 ,1 -dimethylethyl)-2- azetidinone of the formulae 1-3 defined as above.
  • the main objective of the present invention is to separate optically pure ester (+)-c/s-(3fi,4R)-3-acetoxy-1-(4-methoxyphenyl)-4-(2-furanyl)-2-azetidinone of formula 1a, (+)-c/s-(3R,4f?)-3-acetoxy-1-(4-methoxyphenyl)-4-(2-thiophenyl)-2- azetidinone of formula 2a and (+)-c/s-(3R,4S)-3-acetoxy-4-(1 ,1-dimethylethyl)-2- azetidinone of formula 3a from the racemic mixture using Arthrobacter simplex (RRL-1) lipase.
  • RRL-1 Arthrobacter simplex
  • Another objective of the present invention is provide stereoselective hydrolysis of respective racemic esters i.e. hydrolysis of ( ⁇ )-c/s-3-hydroxy-1-(4- methoxyphenyl)-4-(2-furanyl)-2-azetidinone of formula 1, ( ⁇ )-c/s-3-hydroxy-1-(4- methoxyphenyl)-4-(2-thiophenyl)-2-azetidinone of formula 2 and ( ⁇ )-c/s-3-hydroxy- 4-(1 ,1-dimethylethyl)-2-azetidinone of formula 3.
  • the present invention provides a process for stereoselective enzymatic resolution of a racemic mixture of ( ⁇ )-c/s-3-acetoxy-1-(4- methoxyphenyl)-4-(2-furanyl)-2-azetidinone (1 ), ( ⁇ )-c/s-3-acetoxy-1 -(4- methoxyphenyl)-4-(2-thiophenyl)-2-azetidinone (2) or ( ⁇ )-c/s-3-acetoxy-4-(1 ,1- dimethylethyl)-2-azetidinone (3), which comprises incubating the racemic compound selected from the structural formulae 1-3 shown in the drawing accompanying this specification with a crude wet pellet of whole cell preparations or cell free preparation or isolated/partially purified lipase enzyme (RRL-1)
  • Arthrobacter simplex in an aqueous buffer phase in presence of an organic co-solvent for effecting stereoselective hydrolysis of racemic acyl derivatives, at a temperature of 10-40 0 C, for a period of period of 12-15 hrs, followed by separation of unhydrolysed ester and hydrolyzed alcohol from the resultant mixture by known chromatography methods to obtain the deired resolved products (+)-c/s-(3R,4R)-3-acetoxy-1-(4-methoxyphenyl)-4-(2-furanyl)-2-azetidinone of formula 1a and hydrolysed alcohol (-)-c/s-(3S,4S)-3-hydroxy-1-(4- methoxyphenyl)-4-(2-furanyl)-2-azetidinone of formula 1b; unhydrolysed ester (+)- CiS-(ZRAR)-S-ZCeXoXy-I -(4-methoxyphenyl)
  • the racemic mixture used is selected from the compounds of formulae 1-3.
  • aqueous buffer phase used is selected from the group consisting of phosphate buffer, tris buffer and acetic acid buffer.
  • the organic co-solvent used is selcted from selected from the group consisting of hexane, cyclohexane, benzene, toluene, dichloromethane, acetone, acetonitrile, dimethylformamide, dimethyl sulphoxide, methanol and ethanol.
  • concentrations of organic co-solvent used is in the range of 10-90%.
  • reaction temperature used is preferably in the range of 20-35 0 C.
  • the pH of the reaction mixture is in the range of 5-8.
  • the product obtained after resolution has >99% enantiomeric excess.
  • racemic mixtures of the title compounds of formulae 1-3 were initially synthesised by 2+2 cycloaddition reaction of acetoxyacetyl chloride and an imine in presence of a base in an organic solvent at a specified temperature by the method known in the art of its synthesis.
  • Arthrobacter simplex is a bacteria which is gram positive, obligate aerobe and it grows as rod (motile) and coccai (Non motile) form. Under microscope the cells appears as chevrons (V- shape).
  • racemic substrate of formulae 1-3 is incubated with crude wet pellet of whole cell or cell free preparation or isolated/partially purified enzyme of Arthrobacter simplex (RRL-1) in an aqueous phosphate buffer selected from buffers such as phosphate, tris and acetic acid and the like at pH in the range of 5 to 8.
  • aqueous phosphate buffer selected from buffers such as phosphate, tris and acetic acid and the like at pH in the range of 5 to 8.
  • the stereoselective hydrolysis of the racemic substrate of formulae 1-3 is most efficiently effected in presence of an organic co-solvent which not only improves the enantioselectivity but also significantly improves the rate of hydrolysis.
  • the co-solvent used are selected from non polar as well as polar solvents such as toluene, benzene, hexane, cyclohexane, xylene, dimethylformamide, acetonitrile, dimethyl sulphoxide, dichloromethane, diethyl ether and the like, whereas the preferred co-solvents are dimethylformamide, acetonitrile or dimethyl sulphoxide.
  • the biphasic solvent system preferably comprises the preferred ratios of the two phases in the range between 10 to 90 percent by volume of organic phase and between about 90 to 10 percent by volume of aqueous phase, more suitably a biphasic medium comprising 90 and 10 percents by volume of buffer and organic co-solvent respectively.
  • the pH of the buffer medium is suitably adjusted at 5-8, more suitably at 6- 7.5 and most suitably at 7.
  • the temperature of the reaction is selected between 10- 4O 0 C, more suitably at 20-35 0 C and most suitably at 26 ⁇ 1°C.
  • Racemic ( ⁇ )-c/s-3-acetoxy-1-(4-methoxyphenyl)-4-(2-furanyl)-2-azetidinone (1g) of formula 1 was added to biphasic system of aqueous phosphate buffer (22.5ml, 0.1 M. pH 7.0) and organic solvent dimethylformamide (2.5ml).
  • aqueous phosphate buffer (22.5ml, 0.1 M. pH 7.0) and organic solvent dimethylformamide (2.5ml).
  • RRL- 1g Arthrobacter simplex
  • TLC was performed on silica gel coated glass plates, using ethyl acetate: hexane (40:60) as mobile phase.
  • Chiral HPLC was performed on Shimadzu HPLC using (R, R) Whelk-O1 chiral column and hexane: isopropyl alcohol: acetic acid, 97:3:0.1 as mobile phase.
  • the reaction was terminated by adding ethyl acetate and centrifuging the mixture at 10,000 to 15,00Og to remove enzyme and the suspended particles. The clear solution was decanted and the centrifuged mass was extracted separately with ethyl acetate (3 x 50ml).
  • Racemic ( ⁇ )-c/s-3-acetoxy-1-(4-methoxyphenyl)-4-(2-thiophenyl)-2-azetidinone (200mg) of formula 2 was added to biphasic system of aqueous phosphate buffer (9ml, 0.1 M. pH 7.0) and organic solvent dimethylformamide (1ml).
  • aqueous phosphate buffer 9ml, 0.1 M. pH 7.0
  • organic solvent dimethylformamide 1ml
  • RRL- 1 Arthrobacter simplex
  • TLC was performed on silica gel coated glass plates, using ethyl acetate: hexane (40:60) as mobile phase.
  • Chiral HPLC was performed on Shimadzu HPLC using (R, R) Whelk-O1 chiral column and Hexane:isopropyl alcohol: acetic acid, 97:3:0.1 as mobile phase.
  • the reaction was terminated by adding ethyl acetate and centrifuging the mixture at 10,000 to 15,00Og to remove enzyme and the suspended particles. The clear solution was decanted and the centrifuged mass was extracted separately with ethyl acetate (3 x 50ml). The organic layer was combined and washed with water.
  • Racemic ( ⁇ )-c/s-3-acetoxy-4-(1 ,1-dimethylethyl)-2-azetidinone (135 mg of formula 3 was added to biphasic system of aqueous phosphate buffer (9.0ml, 0.1 M. pH 7.0) and organic dimethylformamide (1.0ml).
  • aqueous phosphate buffer 9.0ml, 0.1 M. pH 7.0
  • organic dimethylformamide 1.0ml
  • TLC was performed on silica gel coated glass plates, using ethyl acetate:hexane (40:60) as mobile phase.
  • Chiral HPLC was performed on Shimadzu HPLC using Diacel OJ-H column and Hexane:ethyl alcohol, 98:2 as mobile phase. After completion of the reaction (2-4h., approx., 50% conversion), the reaction was terminated by adding ethyl acetate and was extracted separately with ethyl acetate (3 x 25ml). The organic layer was combined and washed with water.
  • Racemic ( ⁇ )-c/s-3-acetoxy-1 -(4-methoxyphenyl)-4-(2-furanyl)-2-azetidinone (0.5g) of formula 1 was added to biphasic system of aqueous phosphate buffer (12ml, 0.1 M. pH 7.0) and organic solvent dimethylformamide (1.5ml).
  • aqueous phosphate buffer (12ml, 0.1 M. pH 7.0) and organic solvent dimethylformamide (1.5ml).
  • RRL-1 Arthrobacter simplex
  • RRL-1 Arthrobacter simplex
  • HPLC chiral high performance liquid chromatography
  • TLC was performed on silica gel coated glass plates, using ethyl acetate: hexane (40:60) as mobile phase.
  • Chiral HPLC was performed on Shimadzu HPLC using (R, R) Whelk-O1 chiral column and hexane: isopropyl alcohol: acetic acid, 97:3:0.1 as mobile phase.
  • the reaction was terminated by adding ethyl acetate and was extracted separately with ethyl acetate (3 x 20ml). The organic layer was combined and washed with water.
  • Racemic ( ⁇ )-c/s-3-acetoxy-1 -(4-methoxyphenyl)-4-(2-furanyl)-2-azetidinone (0.5g) of formula 1 was added to biphasic system of aqueous phosphate buffer (12ml, 0.1 M. pH 7.0) and organic solvent dimethylformamide (1.5ml).
  • aqueous phosphate buffer (12ml, 0.1 M. pH 7.0) and organic solvent dimethylformamide (1.5ml).
  • lypholysed cell free preparation of Arthrobacter simplex (RRL- 1) 0.25g, (2060 units/mg) was added. During the course of the reaction temperature was maintained at 30 ⁇ 1°C.
  • Thin layer chromatography (TLC) and chiral high performance liquid chromatography (HPLC) was carried out to monitor the progress of the reaction after every hour.
  • TLC was performed on silica gel coated glass plates, using ethyl acetate: hexane (40:60) as mobile phase.
  • Chiral HPLC was performed on Shimadzu HPLC using (R, R) Whelk-01 chiral column and hexane: isopropyl alcohol: acetic acid, 97:3:0.1 as mobile phase.
  • the reaction was terminated by adding ethyl acetate and was extracted separately with ethyl acetate (3 x 20ml). The organic layer was combined and washed with water.
  • Arthrobacter simplex Advantage of using Arthrobacter simplex is that the enzymatic preparation is highly stereoselective that hydrolyses only one of the enantiomers, thereby furnishing both the enantiomers in high optical purity (enantiomeric excess, ee ⁇ 99%) with high time space yields.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un traitement enzymatique stéréosélectif destiné à la résolution d'un mélange à base de (±)-cis-3-acétoxy-1-(4-méthoxyphényl)-4-(2-furanyl)-2- azétidinone, de (±)-cis-3-acétoxy-1-(4-méthoxyphényl)-4-(2-thiophényl)-2-azétidinone ou de (±)-cis-3-acétoxy-4-(1,1-diméthyléthyl)-2-azétidinone dans leur formes optiquement pures au moyen d'une lipase. L'invention concerne en l'occurrence l'utilisation d'un simplex d'Arthrobacter à lipase native (MTCC 5125) dans un processus de résolution hautement efficace destiné à la séparation de deux énantiomères de (±)-c/s-3-acétoxy-1-(4-méthoxyphényl)-4- (2-furanyl)-2-azétidinone, de (±)-c/s-3-acétoxy-1-(4-méthoxyphényl)-4-(2-thiophényl)-2- azétidinone et de (±)-c/s-3-acétoxy-4-(1,1-diméthyléthyl)-2-azétidinone par une hydrolyse stéréosélective de leurs acétyl-esters en présence d'un co-solvant organique.
PCT/IN2008/000722 2008-03-26 2008-10-31 Hydrolyse stéreosélective pour la résolution de mélanges racémiques à base de (±) -cis-s-acétoxy-1- (4-méthoxyphényl) -4- (2-furyl) -2-azétidinone, de (±) -cis-s-acétoxy-1- (4-méthoxyphenyl) -4- (2-thiényl) -2-azétidinone, ou de (±)-cis-3-acétoxy-4-(1,1-diméthyléthyl)-2-azétidinone WO2009118750A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN778DE2008 2008-03-26
IN778/DEL/2008 2008-03-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/139,492 A-371-Of-International US20120001412A1 (en) 2008-12-15 2009-12-15 Surface Modified Optically Variable Product for Security Feature
US15/269,365 Division US20170002222A1 (en) 2008-12-15 2016-09-19 Surface modified optically variable product for security feature

Publications (1)

Publication Number Publication Date
WO2009118750A1 true WO2009118750A1 (fr) 2009-10-01

Family

ID=40456754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000722 WO2009118750A1 (fr) 2008-03-26 2008-10-31 Hydrolyse stéreosélective pour la résolution de mélanges racémiques à base de (±) -cis-s-acétoxy-1- (4-méthoxyphényl) -4- (2-furyl) -2-azétidinone, de (±) -cis-s-acétoxy-1- (4-méthoxyphenyl) -4- (2-thiényl) -2-azétidinone, ou de (±)-cis-3-acétoxy-4-(1,1-diméthyléthyl)-2-azétidinone

Country Status (1)

Country Link
WO (1) WO2009118750A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0552041A2 (fr) * 1992-01-15 1993-07-21 E.R. Squibb & Sons, Inc. Procédés enzymatiques pour la résolution d'un mélange d'énantiomères efficaces comme intermédiaires dans la préparation de taxanes
US6548293B1 (en) * 1999-10-18 2003-04-15 Fsu Research Foundation, Inc. Enzymatic process for the resolution of enantiomeric mixtures of β-lactams

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0552041A2 (fr) * 1992-01-15 1993-07-21 E.R. Squibb & Sons, Inc. Procédés enzymatiques pour la résolution d'un mélange d'énantiomères efficaces comme intermédiaires dans la préparation de taxanes
US6548293B1 (en) * 1999-10-18 2003-04-15 Fsu Research Foundation, Inc. Enzymatic process for the resolution of enantiomeric mixtures of β-lactams

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANAND, N. ET AL.: "(3R,4S)-cis-3-Acetoxy-1-(4-methoxyphenyl)-4-(2-furanyl)azetidin-2-one", ACTA CRYSTALLOGRAPHICA SECTION E, vol. 6, no. 7, July 2004 (2004-07-01), pages 1215 - 1216, XP002521282, Retrieved from the Internet <URL:http://scripts.iucr.org/cgi-bin/paper?S1600536804014540> [retrieved on 20090325] *
ANAND, N. ET AL.: "Arthrobacter sp.: a lipase of choice for the kinetic resolution of racemic arylazetidinone precursors of taxanoid side chains", TETRAHEDRON ASYMMETRY, vol. 18, no. 9, 7 June 2007 (2007-06-07), pages 1059 - 1069, XP022107696 *

Similar Documents

Publication Publication Date Title
JP3184350B2 (ja) タキサン類の製造中間体として有用な化合物のエナンチオマー混合物の酵素分割法
AU688766B2 (en) Enzymatic processes for the resolution of enantiomeric mixtures of compounds as intermediates in the preparation of taxanes
Bonini et al. Enzyme catalysed lactonization of 3, 5 dihydroxy esters: Enantioselective synthesis of naturally occurring 3-hydroxy-5-decanolide,(−)-massoialactone, and 3-hydroxy-5-icosanolide.
Solares et al. Enzymatic resolution of a quaternary stereogenic centre as the key step in the synthesis of (S)-(+)-citalopram
EP0605033B1 (fr) Procédé enzymatique pour la préparation stéréoselective, d&#39;un enantiomère d&#39;un alcool hétérobicyclique
JPH06172276A (ja) β−ラクタム前駆体からタキソール型化合物を製造する方法
Anand et al. Arthrobacter sp.: a lipase of choice for the kinetic resolution of racemic arylazetidinone precursors of taxanoid side chains
Patel et al. Biocatalytic synthesis of some chiral pharmaceutical intermediates by lipases
WO2009118750A1 (fr) Hydrolyse stéreosélective pour la résolution de mélanges racémiques à base de (±) -cis-s-acétoxy-1- (4-méthoxyphényl) -4- (2-furyl) -2-azétidinone, de (±) -cis-s-acétoxy-1- (4-méthoxyphenyl) -4- (2-thiényl) -2-azétidinone, ou de (±)-cis-3-acétoxy-4-(1,1-diméthyléthyl)-2-azétidinone
EP1601778B1 (fr) Procede chimioenzymatique stereoselectif pour la preparation de phenylglycidates optiquement enrichis
US6020174A (en) Chemoenzymatic synthesis of the taxol C-13 side chain N-benzolyl- (2R,3S)-Phenylisoserine
JP4633934B2 (ja) 光学活性な１−アミノ−４−（ヒドロキシルメチル）−シクロペンタ−２−エン誘導体の製造方法
JP2004525086A (ja) 鏡像異性体的に純粋なヒドロキシエステルおよび酸の製造方法
KR20070076549A (ko) 광학적으로 활성인 사이클로펜텐온의 제조방법 및 그로부터제조된 사이클로펜텐온
Izumi et al. Enzymatic resolution of trans‐2, 3‐dihydro‐3‐hydroxy‐2‐phenyl‐4H‐1‐benzopyran‐4‐one (trans‐flavanon‐3‐ol) by lipase
EP0264429A1 (fr) PROCEDE ENZYMATIQUE POUR LA PREPARATION DE DERIVES DE L&#39;ACIDE 1,2-DIHYDRO-3H-PYROLLO 1,2a]PYRROLE-1-CARBOXYLIQUE OPTIQUEMENT ACTIFS
Varma et al. Lipases catalyzed enantioselective hydrolysis of (R, S)-methyl 1, 4-benzodioxan-2-carboxylate intermediate for (S)-doxazosin mesylate
Miyazawa et al. Chromobacterium viscosum lipase catalyzes the transesterifications at the carboxyl site as well as the hydroxy site during the enzymatic enantioselective alcoholysis of O-acylated mandelates
JPH04258297A (ja) 光学活性１−フェニル−１、３−プロパンジオールおよびその誘導体の製造法
HU213569B (en) Enzymatic process for the stereoselective preparation of a heterobicyclic alcohol enantiomer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08873621

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08873621

Country of ref document: EP

Kind code of ref document: A1